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Key Points 
• The polyfunctionality strength index of manufactured CAR T cells were associated with 
clinical response and toxicities. 
• Monitoring CAR T-cell polyfunctionality as a key product attribute may complement other 
characteristics including T-cell proliferation. 
Abstract 
After treatment with chimeric antigen receptor (CAR) T cells, interleukin (IL)-15 elevation and 
CAR T-cell expansion are associated with non-Hodgkin lymphoma (NHL) outcomes. However, 
the association of preinfusion CAR product T-cell functionality with clinical outcomes has not 
been reported. A single-cell analysis of the preinfusion CD19 CAR product from patients with 
NHL demonstrated that CAR products contain polyfunctional T-cell subsets capable of 
deploying multiple immune programs represented by cytokines and chemokines including 
interferon-γ (IFN-γ), IL-17A, IL-8, and macrophage inflammatory protein 1-α. A prespecified T-
cell polyfunctionality strength index (PSI) applied to preinfusion CAR product was significantly 
associated with clinical response, and PSI combined with CAR T cell-expansion or pretreatment 
serum IL-15 levels conferred additional significance. Within the total product cell population, 
associations with clinical outcomes were greater with polyfunctional CD4+ T cells compared 
with CD8+ cells. Grade 3+ cytokine release syndrome was associated with polyfunctional T 
cells, and both grade 3+ neurologic toxicity (NT) and antitumor efficacy were associated with 
polyfunctional IL-17A–producing T cells. The findings in this exploratory study show that a 
preinfusion CAR product T-cell subset with a definable polyfunctional profile has a major 
association with clinical outcomes of CAR T-cell therapy.  
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Introduction 
Genetic reprograming of T cells to express a chimeric antigen receptor (CAR) offers a novel 
approach for treating hematologic malignancies.1-3 T cells transduced with an anti-CD19 CAR 
composed of CD28 and CD3ζ signaling domains produce interferon-γ (IFN-γ) in a CD19-specific 
manner, kill primary leukemia cells, and undergo CD19-target dependent proliferation.4 
Treatment of B-cell malignancies with anti-CD19 CAR T cells results in durable remissions in a 
significant number of patients. This treatment is associated with B-cell aplasia due to 
endogenous CD19 expression on B cells. Additionally, treatment with anti-CD19 CAR T cell-
therapy can cause cytokine release syndrome (CRS) and neurologic toxicity (NT). Anti-CD19 
CAR T cell-therapy has not yet been fully characterized mechanistically.5,6 An optimized, low-
dose conditioning chemotherapy regimen of cyclophosphamide and fludarabine has been 
shown to enhance engraftment of CAR T cells through lymphodepletion and by increasing 
serum cytokine levels, most notably interleukin (IL)-15.6 Levels of IL-15 are correlated with CAR 
T-cell expansion, which in turn correlated with clinical response and toxicities.6 This study also 
showed that greater expansion of CAR T cells in blood and higher serum levels of IL-15, 
granzyme B, and IL-10 were associated with grade 3 or higher NT.6    
 
T cells deploy a broad spectrum of immune programs,7 and it is unclear which specifically 
influence in vivo expansion and activity of CAR T cells. We hypothesized that CAR T cells 
orchestrate clinical activity by deploying multiple immune programs that functionally complement 
each other. To address this hypothesis, we evaluated CAR T-cell product functionality using a 
high-content single-cell multiplex cytokine analysis8,9 that allowed for identification of a subset of 
polyfunctional T cells in CAR T-cell products that produce 2 or more cytokines upon stimulation 
with CD19 antigen in vitro. We also examined associations of a prespecified polyfunctionality 
strength index (PSI) applied to CAR T-cell products, CAR T-cell expansion in vivo, objective 
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response (OR), and toxicities. We show that highly polyfunctional T cells within CAR T-cell 
products are significantly associated with clinical response and that a subset of polyfunctional 
CD4+ T cells producing IL-17A is associated with grade 3 or higher NT. 
 
Methods 
Patient demographics and treatment protocol  
The study (NCT00924326) cohort comprised 22 patients with recently described clinical 
outcomes.6 Of 22 treated patients, 19 had diffuse large B-cell lymphoma (DLBCL), 2 had 
follicular lymphoma, and 1 had mantle cell lymphoma (Table 1). Of 19 patients with DLBCL, 11 
had chemotherapy-refractory lymphoma. Five patients with DLBCL had lymphoma that relapsed 
10 months or less after autologous stem cell transplant as their last treatment before protocol 
enrollment. Eleven patients with DLBCL were high risk, according to the second-line, age-
adjusted International Prognostic Index.10 The median number of unique lymphoma therapies 
received before protocol enrollment was 4 (range, 1-7). Products from 20 patients were 
evaluable by single-cell multiplex cytokine profiling and used in this exploratory study (Table 1). 
Objective response (OR) is defined as partial (PR) or complete (CR) defined by Cheson 2014 
criteria.27 Stable (SD) and progressive disease (PD) correspond to lack of objective response 
(non-responders). CRS and NT were graded as previously reported.6 
 
T-cell polyfunctionality evaluation by single-cell cytokine profiling and calculation of PSI  
Cryopreserved CAR T-cell products comprising about 40%-60% CAR+ T cells, measured by 
surface expression of the scFv by flow cytometry, were thawed and cultured in complete Cell 
Therapy Systems (CTS) (Thermo Fisher Cell Therapy Systems, Waltham, MA) medium with IL-
2 (10 ng/mL, Biolegend, San Diego, CA) at a density of 1 × 106/mL in a 37°C, 5% 
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CO2 incubator. After overnight recovery, viable T cells were enriched using Ficoll-Paque Plus 
medium (Fisher Scientific, Pittsburgh, PA). CD4+/CD8+ T-cell subsets were separated using 
anti-CD4 or anti-CD8 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and 
stimulated with K562 cells transduced with either CD19 or nerve growth factor receptor (NGFR) 
at a ratio of 1:2 for 20 hours at 37°C, 5% CO2. The co-cultured CD4+ or CD8+ T cells were 
further enriched using anti-CD19 or anti-NGFR–conjugated magnetic beads to deplete CD19-
K562 or NGFR-K562 cells. Presence of CD4+ or CD8+ CAR T cells was confirmed by staining 
with Alexa Fluor 647 (Thermo Fisher Cell Therapy Systems, Waltham, MA) conjugated anti-CD4 
or anti-CD8 antibody at room temperature for 10 minutes, rinsed once with phosphate-buffered 
saline, and resuspended in complete CTS medium at a density of 1 × 106/mL. Approximately 30 
µL of the cell suspension was loaded into the single-cell barcode chip (SCBC) microchip9 for 
single-cell secretomics evaluation. 
 
For each sample, a 32-plex assay measured secreted proteins from ∼2000 T cells (Figure 1). 
Raw microscopy and microarray scans of the cell samples (loaded onto the SCBC) and protein 
secretion data were analyzed using proprietary image processing software to determine the 
locations of chambers containing single cells and subsequent extraction of their secretion 
readouts. Data from empty cell chambers were used to measure background intensity levels for 
each analyzed protein. Single-cell readouts were then normalized using the background 
readouts to determine significant secretions and compare profiles across assays. Proprietary 
software and the R statistical package (R Foundation for Statistical Computing, Vienna, Austria) 
were used for statistical data analysis and visualizations. 
 
A single cell functional profile was determined for each evaluable product. Profiles were 
categorized into effector (Granzyme B, IFN-γ, MIP-1α, Perforin, TNF-α, TNF-β), stimulatory 
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(GM-CSF, IL-2, IL-5, IL-7, IL-8, IL-9, IL-12, IL-15, IL-21), regulatory (IL-4, IL-10, IL-13, IL-22, 
TGF-β1, sCD137, sCD40L), chemoattractive (CCL-11, IP-10, MIP-1β, RANTES), and 
inflammatory (IL-1b, IL-6, IL-17A, IL-17F, MCP-1, MCP-4) groups. Polyfunctional CAR product T 
cells were defined as cells co-secreting at least 2 proteins from the prespecified panel per cell 
coupled with the amount of each protein produced (ie, combination of number of proteins 
secreted and at what intensity). Cutoffs for any given cytokine were computed based on 
background levels in wells with zero cells + 3SD. Knowing the functional profile of each cell 
enables the calculation of other metrics, including a breakdown of each sample according to cell 
polyfunctionality (ie, what percentage of cells are secreting multiple cytokines versus 
nonsecreting or monofunctional cells), and a breakdown of the sample by functional groups (ie, 
which mono- and polyfunctional groups are being secreted by cells in the sample, and their 
frequency).  
 
Furthermore, the PSI of each sample was computed using a prespecified formula,8 defined as 
the percentage of polyfunctional cells, multiplied by mean fluorescence intensity (MFI) of the 
proteins secreted by those cells:  
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The CD4+ and CD8+ PSIs were computed for corresponding CD19-K562 or NGFR-K562 
stimulated samples from each donor. An overall PSI, (the average of CD4+ and CD8+ PSI), was 
also computed.  
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The CD4+ PSI calculation was performed by analyzing all polyfunctional CD4+ cell readouts of 
the sample. Each readout was an n-dimensional vector (n = number of analyzed cytokines) of 
signal intensities (MFI, random fluorescence intensity). The average signal intensity of each 
cytokine was found across the set of polyfunctional cells. Multiplying this number by the fraction 
of polyfunctional cells provided the individual cytokine PSI values (eg, IL-17A CD4+ PSI). The 
sum of all the individual cytokine PSI values provided the overall CD4+ PSI for the sample. The 
same calculation was performed to find the CD8+ PSI and each cytokine's individual CD8+ PSI. 
Averaging CD4+ and CD8+ PSIs provided the overall PSI index for each sample. We also 
calculated a monofunctional strength index, or MSI metric, defined as the percentage of 
monofunctional cells multiplied by the secretion intensity of that cytokine. 
 
Any notable statistically significant associations between preinfusion single-cell CAR T data and 
clinical outcome were determined, cognizant of the clinical outcome of these patients (OR, CRS, 
and NT). More specifically, associations between overall PSI, CD4+ PSI, CD8+ PSI, IL-17A 
CD4+ PSI, and clinical outcomes were determined. Mann-Whitney U tests were used to 
determine P values of these associations. Any associations between single-cell metrics (eg, 
PSI) and other pre- and postinfusion metrics described throughout this paper (eg, in vivo CAR 
T-cell expansion, IL-15 day 0 patient levels, co-culture and serum cytokine levels, T-cell 
phenotype frequencies) were determined by measuring the Spearman correlation between 
these metrics.  
 
In some cases, 2 metrics were combined into a joint metric to test their association with patient 
outcome. The metrics were added to each other after each was first standardized to have unit 
variance. This standardization was achieved by dividing the metrics by their respective standard 
deviation to bring them to a common magnitude/scale. Thus, when added to one other, the 
metrics carry a similar weight and one does not "overpower" the other. 
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Measurement of in vivo CAR T-cell levels  
CAR T-cell presence and expansion in blood was measured by quantitative polymerase chain 
reaction PCR (qPCR) as previously described.5 
 
Measurement of cytokines in co-culture and serum by multiplex analysis  
Co-culture experiments were performed using K562 cells engineered to express CD19 or NGFR 
(negative control) mixed 1:1 with CAR T-cell product. Cell culture medium was harvested 24 
hours postincubation for subsequent analysis. Thirty-one analytes were evaluated by Meso 
Scale Discovery (MSD; Rockville, MD), MULTI-SPOT, and EMD Millipore (Burlington, MA) 
Luminex xMAP multiplex assays. Serum IL-15 was measured using EMD Millipore Luminex 
xMAP multiplex assays. Data acquisition and analysis were performed using a Luminex 200 
instrument and xPONENT 3.1 data analysis software. 
 
Evaluation of percentage of T17 and Treg cells by epigenetic analysis 
Epigenetic analysis was performed based on previously characterized methods,11 at Epiontis 
GmbH (Berlin, Germany). Genomic DNA was isolated using the DNeasy tissue kit (Qiagen) 
following the protocol for cultured animal cells. Bisulfite treatment of genomic DNA was 
performed. A PCR was performed in a final volume of 25µL containing 1× PCR buffer, 1U Taq 
DNA polymerase (Qiagen), 200µmol/L dNTP, 12.5pmol each of forward and reverse primers, 
and 7ng bisulfite-treated genomic DNA at 95°C for 15minutes, and 40 cycles of 95°C for 
1minute, 55°C for 45seconds and 72°C for 1minute, and a final extension step of 10minutes 
at 72°C. The PCR products were purified using ExoSAP-IT (USB Corp, Cleveland, OH) and 
sequenced by applying the PCR primers and the ABI Big Dye Terminator v1.1-chemistry 
(Applied Biosystems) followed by capillary electrophoresis on an ABI 3100 genetic analyzer; 
ESME was used to interpret AB1 files. 
For personal use only.on June 18, 2018. by guest  www.bloodjournal.orgFrom 
ROSSI et al. POLYFUNCTIONAL CAR T CELL-ASSOCIATED CLINICAL OUTCOMES 
9 
 
 
Determination of product T-cell phenotypes by flow cytometry 
For CD4, CD8, and central memory phenotype determination, we utilized a method similar to 
one described previously.5 CAR+ CD3+ events were gated and the percentage of cells 
expressing memory markers CCR7 and CD45RA was determined. Appropriate isotype control 
antibodies were used in all experiments. The memory antibodies used were anti-CD45RA 
(eBioscience, San Diego, CA clone HI100) and anti-CCR7 (R&D Systems clone 150503). 
 
Gene expression analysis  
Gene expression analysis was performed at NanoString Technologies (Seattle, WA). 
Cryopreserved cells were thawed and enumerated using a Vi-CELL automated cell counter 
(Beckman Coulter, Brea, CA). Live cell suspensions were used as input into the NanoString 
Vantage 3D RNA:Protein Immune Cell Profiling Panel (NanoString Technologies), a 770-plex 
gene and 30-plex protein expression panel that profiles the human immune response. For 
CD19-K562 or NGFR-K562 samples, 50 000 cells were used for RNA and 100 000 cells for 
protein. For K562 plus CAR T cell co-cultures, 150 000 cells were used for RNA and 200 000 
cells for protein. For CAR T cells, 300 000 cells were used for RNA and 200 000 cells for protein. 
A custom gene expression panel of 191 additional immune and metabolic-related markers, 
including probes specific for the anti-CD19 CAR, was run on cell lysates made for the 
RNA:Protein assay. Raw data were imported from the MAX digital analyzer into nSolver 
software v3.0 (NanoString Technologies). Standard quality control checks assessing imaging, 
binding density, positive control linearity, and limit of detection were performed. By utilizing 
internal positive controls in the panels, raw gene and protein expression data were first 
normalized. The mRNA data were further normalized by the geometric mean of a set of stably 
expressed reference genes and the protein data were normalized by the geometric mean of a 
set of stably expressed proteins. The mRNAs and proteins expressed below background were 
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filtered from the analysis using cutoffs of mean + 2 standard deviations of negative controls (for 
mRNA), and 3 × geometric mean of immunoglobulin G-negative controls (for protein). 
 
RESULTS 
 
Preinfusion CAR T Cell-product polyfunctional profiles are associated with clinical 
response and toxicities 
The polyfunctional profiles of CAR product T cells stimulated with CD19+ cells were dominated 
by effector molecules, stimulatory/proliferative cytokines, and chemokines. Detailed evaluation 
including principal component analysis showed a complex and heterogeneous functional profile 
of product T cells, with both polyfunctional CD4+ and CD8+ T-cell subsets secreting 
predominantly IFN-γ, IL-8, IL-5, granzyme B, and/or (macrophage inflammatory protein) MIP-1α 
(supplemental Figure 1). Notably, the CD4+ but not CD8+ T-cell population also contained IL-
17A+ polyfunctional T cells. 
 
Overall, products displayed a wide range of PSI values; the polyfunctional cells comprised about 
20% to 25% of all cytokine-producing product T cells. Global product PSI was significantly 
associated with OR (P = .0119; Figure 2). The median PSI was twice as high for responders 
versus non-responders. Higher product PSI was statistically associated with grade 3+ CRS (P 
=.0174) (Figure 2). In contrast to PSI findings, a similarly computed index corresponding to 
monofunctional T cells in the product did not have associations with OR, grade 3+ NT, or grade 
3+ CRS (data not shown). In addition, in this study of limited sample size, major product 
phenotypes defined by flow cytometry and IFN-γ in co-culture were not associated with clinical 
response (Figure 3). The major cytokines and chemokines produced by product polyfunctional T 
cells in the responding patients comprised IFN-γ, MIP-1α, IL-8 in both CD4 and CD8 T cells, 
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granzyme B in CD8 T cells, and IL-17A and IL-5 in CD4 T cells (Figure 4). These results 
suggest that the combination of frequency and cytokine production levels of polyfunctional T 
cells in the product associate with clinical response and toxicity to treatment with CAR T cells. 
 
Combined indexes of product PSI and CAR T cell expansion or pre-CAR T cell- infusion 
levels of IL-15 correlated strongly with clinical response and toxicities  
After infusion, CAR T cells rapidly expand, with peak levels occurring within the first 7 to 14 
days. CAR T-cell expansion, measured as peak and cumulative levels during the first month 
after infusion, is associated with OR and grade 3+ NT, but not grade 3+ CRS.6 
 
Because both CAR T-cell expansion in vivo and product PSI individually correlated with OR, we 
tested the impact of a composite index integrating PSI and CAR T-cell expansion on the 
correlation with OR. This index was computed by adding the 2 metrics to each other, after first 
standardizing them to have comparable variances (see Methods). This composite index 
combining PSI and CAR T-cell expansion improved the association with OR (P = .0046, not 
adjusted for multiplicity) compared to each covariate alone (Figure 5). Furthermore, OR 
associated with CD4+ PSI plus CAR peak levels (P = .0023), but only marginally with CD8+ PSI 
plus CAR peak levels, respectively (P = .0507; supplemental Figure 2). There was no apparent 
association between CAR peak levels and PSI (supplemental Figure 3). These results suggest 
that PSI in conjunction with CAR T-cell expansion may associate with clinical outcome to CAR 
T-cell therapy. 
 
Because PSI was not significantly associated with commonly assessed product phenotypes 
based on CCR7 and CD45RA expression (Figure 3), we sought to identify other potential 
product characteristics associated with PSI. We hypothesized that the anti-CD19 CAR construct 
enabled the polyfunctionality of product T cells. Therefore, CAR gene expression levels were 
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measured by NanoString (Seattle, WA) in bulk product together with T-cell housekeeping 
molecules. Global PSI was associated with the ratio between CAR mRNA copies and T-cell–
specific markers (supplemental Table 1). This finding suggests that product CAR expression 
level influences product T-cell polyfunctionality.  
 
In contrast to PSI alone, combining product PSI or CD4+ PSI with CAR peak levels, 
respectively, was significantly associated with grade 3+ NT (supplemental Figure 4A). As 
specified in Methods, CD4+ and CD8+ PSIs were calculated for each product by applying the 
same prespecified formula to the 2-product T-cell subsets separately. Based on these findings 
and the putative pathogenic role of Th17 cells,12,13 we asked whether subsets of polyfunctional T 
cells producing cytokines including IL-17A were associated with grade 3+ NT. Cytokine-specific 
PSI was computed by multiplying the percentage of polyfunctional T cells secreting a given 
cytokine with the average signal intensity for that cytokine. These cytokine PSI values were 
analyzed in relation to outcome. Interestingly, IL-17A PSI, defined post hoc, plus CAR peak cell 
levels, had a significant association with grade 3+ NT (P =.0007; supplemental Figure 4A). 
Individually, CAR peak cell levels and IL-17A PSI were associated with grade 3+ NT (P = .0015 
and P = .0574, respectively). To strengthen these findings, we explored other product attributes 
that may relate to IL-17A PSI. As expected, IL-17A PSI correlated strongly with the percentage 
of Th17 cells measured by epigenetic marking and IL-17A production in product co-culture (P < 
.0001 for both comparisons), and associated with the CD4/CD8 ratio, percentage of T helper 
(Th) cells, and IL-6 levels in product co-culture (supplemental Table 2). In turn, grade 3+ CRS 
was associated with the global product PSI plus CAR peak levels (supplemental Figure 4B).  
 
Because IL-15 levels initially elevated by conditioning chemotherapy were associated with CAR 
T-cell expansion and OR,6 we investigated whether pre-CAR T-cell infusion levels of IL-15, in 
combination with PSI, were associated with clinical outcome. Indeed, product PSI combined 
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with IL-15 levels at day 0 had a statistically significant association with OR (P = .0033). 
Objective response also was associated with PSI (P = .0119) and IL-15 (P = .0153) individually 
(Figure 5). However, PSI and IL-15 on day 0 did not have a statistically significant association 
with each other. IL-15 on day 0 in conjunction with CD4+ PSI, or with IL-17A PSI, were also 
strongly associated with OR (P < .0004; supplemental Figure 2). Finally, day 0 levels of IL-15 + 
IL-17A PSI were associated with grade 3+ NT and CRS (supplemental Figure 5). 
  
These results show that product PSI, together with CAR T-cell expansion or pre-CAR T- cell 
infusion levels of IL-15, contribute jointly to clinical outcomes after CAR T-cell therapy. These 
findings also highlight the prominent role of IL-17A polyfunctional T cells in clinical outcomes, 
particularly NT, associated with CAR T-cell therapy. 
 
DISCUSSION 
  
We describe a novel product attribute for CAR T cells associated with T-cell polyfunctionality 
and correlated with clinical outcome. This polyfunctionality index, combined with conditioning-
driven IL-15—a cytokine with potent T-cell proliferative capabilities19,20—or CAR T-cell 
expansion in vivo6,21-23— associates with clinical outcomes post-CAR T-cell therapy. 
 
The study comprised a cohort of patients with aggressive refractory non-Hodgkin lymphoma 
treated with CAR T cells.6 In response to ex vivo co-culture with CD19+ target cells, product T 
cells rapidly secrete a broad array of cytokines, chemokines, and immune effector molecules. 
These cytokines and chemokines, as well as T-cell characteristics defined by commonly utilized 
phenotypic markers in a heterogeneous population of T cells, were not significantly associated 
with clinical outcomes (data not shown). To understand the parameters that associate with 
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clinical outcome in anti-CD19 CAR T-cell therapy, we characterized product T cells at the 
single-cell level using PSI8 based on the frequency and production levels of 
homeostatic/proliferative, inflammatory, chemotactic, regulatory, and immune effector 
molecules. To perform this analysis, a SCBC platform and a prespecified formula were utilized. 
In brief, product PSI was defined as the percentage of polyfunctional cells multiplied by MFI of 
the cytokines secreted by those cells (Figure 1; details in Methods). 
 
This analysis showed that polyfunctional profiles for both CD4+ and CD8+ T cells stimulated 
with CD19+ target cells were composed of select effector molecules (granzyme B), 
stimulatory/immune modulating cytokines (IFN-γ, IL-5), and chemokines (IL-8, MIP-1α). In 
contrast to CD8+ T cells, the CD4+ T-cell subset also comprised IL-17A-secreting polyfunctional 
cells. The diversity and co-participation of CD4+ and CD8+ T cells to the polyfunctional T-cell 
population is consistent with a CAR product containing a CD28 co-stimulatory domain, which is 
known to play a signaling role in both subsets.4 Strikingly, only 20%-25% of all product cells 
were polyfunctional upon stimulation with CD19-expressing target cells. 
  
The major finding of this study is that clinical response and toxicities resulting from CAR T-cell 
treatment were associated with the PSI of whole product, or defined T-cell subpopulations, 
computed utilizing a prespecified algorithm. Patient 20 is a notable outlier as the patient had a 
high product PSI but failed to achieve an objective response (Figure 2A). In this patient, CAR T 
cells did not expand well. We hypothesize multiple possible reasons, including limited T cell 
proliferative capability and/or an immune exclusionary tumor environment. 
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Because both CAR T-cell expansion in vivo and product PSI individually correlated with OR, we 
explored the impact of a composite index integrating PSI and CAR T-cell expansion and 
association with OR. Similarly, we combined day 0 IL-15 serum levels with product PSI. 
Combined indices of PSI with either peak CAR T-cell levels in blood, or with day 0 IL-15 serum 
levels, had more significant associations with clinical outcomes versus either parameter alone. 
Day 0 IL-15 serum levels, elevated by conditioning chemotherapy,6 were measured just before 
CAR T-cell infusion. Although the number of evaluable patients in this cohort was limited, OR 
was associated with both CD4+ PSI plus day 0 IL-15, as well as IL-17A PSI plus day 0 IL-15. IL-
17A PSI was determined utilizing a formula-specified post hoc analysis to address the 
hypothesis that an IL-17A–producing T-cell subset may preferentially associate with outcomes. 
CD4+ T cells producing IL-17A and IFN-γ can be potent Th cells with the capability to reprogram 
the tumor microenvironment and enable robust, effective immune-mediated responses.14 In 
addition, IL-8 and MIP-1α, co-produced by these polyfunctional Th cells, are well-known 
chemokines for a wide range of immune cells, including lymphocytes and myeloid cells.14-16 
Although the results point to specialized polyfunctional CD4+ T cells correlating with clinical 
response to a greater degree than CD8+ T cells, they do not exclude a role for effector CD8+ T 
cells, consistent with reports of CD8+ T cell effectiveness in metastatic melanoma.17   
 
Grade 3+ NT had the most statistically significant association with IL-17A PSI plus peak CAR 
levels in blood, suggesting the participation of specialized T cells. Grade 3+ CRS correlated with 
whole product PSI plus either CAR peak levels or day 0 serum IL-15 levels. These findings point 
to mechanisms underlying serious adverse events (AEs). The best correlates of grade 3+ NT 
were peak CAR levels in blood and an index combining peak CAR levels in blood plus IL-17A 
PSI. These results raise the possibility that high numbers of IL-17A–producing polyfunctional 
CAR T (Th17) cells in vivo could be implicated in the pathogenesis of serious NT, while also 
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contributing to OR. Previous evidence implicated IL-17A in the pathogenesis of 
neuroinflammation12,13 and participation in antitumor activity.18 Although global product PSI was 
not associated with major T-cell phenotypic markers, it was associated with the level of CAR 
gene expression in product T cells. 
 
Polyfunctional T cells have not been extensively evaluated in the context of engineered T-cell 
therapies, but they were previously analyzed in vaccines and infectious diseases, where their 
presence was associated with increased protective immunity.24,25 Additionally, presence and 
characterization of polyfunctional T cells were reported recently in CAR T cells generated from 
normal subjects.26 
 
Concurrent studies conducted with larger patient cohorts in conjunction with platform 
optimization and comprehensive validation of this methodology are anticipated to enable a 
better understanding of single-cell metrics over other technologies.  
 
In summary, this exploratory study underscores the potential usefulness of monitoring CAR T-
cell polyfunctionality as a key product attribute, complementing other characteristics including T-
cell proliferative capability. Nevertheless, other key questions remain. For instance, if 
polyfunctionality is partially pre-determined by T cell status before manufacturing and if 
polyfunctionality and clinical outcome could be manipulated through optimizing T cell genetic 
programming, the manufacturing process, or dosing strategy. 
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Figure Legends 
Figure 1. Schematic representation of the method used to evaluate T-cell 
polyfunctionality. A) and B): Schematic representations of CAR construct configuration and 
treatment protocol. C) and D): Product T-cell polyfunctionality was assessed by using ELISA 
detection of proteins from each single-cell chamber after T-cell stimulation. E) and F): 
Polyfunctionality was measured through a PSI, spanning a prespecified panel of 32 key 
immunologically relevant molecules across major categories: homeostatic/proliferative, 
inflammatory, chemotactic, regulatory, and immune effector. CAR, chimeric antigen receptor; 
ELISA, enzyme-linked immunosorbent assay; PSI, polyfunctionality strength index. 
 
Figure 2. Association of PSI with OR, and treatment-related AEs. Single-cell product PSI 
was determined for 20 patient donors by using SCBC proteomics analysis of a panel of 32 
secreted cytokines, chemokines, and cytotoxic molecules. Of the 20 patients, 14 had an OR to 
the CAR T-cell therapy. The products were ranked according to CAR T-cell PSI levels, and the 
PSI was associated with the OR (A, C), or grade 3+ CRS (B, D) as indicated. The results are 
shown as patient-level PSI (A, B) and mean ± SE PSI (C, D). All statistical values were 
computed using the Mann Whitney U Test. AE, adverse event; CRS, cytokine release 
syndrome; OR, objective response; SCBC, single-cell barcode chip; SE, standard error. 
 
Figure 3. Association of CAR product polyfunctionality with CD19 recognition and 
clinical outcome. A: PSI of CAR-T cells and CD4+ or CD8+ subsets, ex vivo stimulated with 
CD19+ as compared with CD19- cells (NGFR transfected). B – E: Association between OR and 
product PSI, IFN-γ measured in product co-culture with CD19+ cells, or major product T-cell 
subsets defined by flow cytometry. T-naïve, central memory (cm), effector memory (em) and 
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effector cells (eff) were defined by staining for CD45RA and CCR7. F: Individual P values (Mann 
Whitney U test) corresponding to the strength of association of major product attributes with 
clinical response. IFN-γ, interferon-γ. 
 
Figure 4. Major cytokines driving polyfunctional product CD4+ and CD8+ T cells by CD19 
stimulation that distinguish responders to the therapy from nonresponders. A and B: 
Single-cell proteomics analysis of a panel of 32 secreted cytokines, chemokines, and cytotoxic 
molecules was performed on product T cells from 20 patients treated with CAR T cells. The 
analysis was performed on all product cells or select CD4+ and CD8+ T cells. The product T 
cells were first stimulated with CD19-expressing target cells or control NGFR cells before the 
analysis. The graphs show PSI (mean ± SE) with or without CD19 stimulation for all cells, and 
for CD4+ and CD8+ subsets separately. The main cytokine drivers for each product T-cell 
subpopulation are also shown. C and D: Product CD4+ and CD8+ T-cell PSI profiles were 
broken down per cytokine, between patient groups with no response, and OR to CAR T-cell 
therapy. Only CD4 and CD8 cytokines that were upregulated relative to mock stimulation were 
shown. Each cytokine PSI level reflects its average secretion intensity in polyfunctional single 
cells. The diagram shows the cytokines that contribute to the polyfunctionality index in the CD8+ 
and CD4+ T-cell populations. NGFR, nerve growth factor receptor. 
 
Figure 5. PSI in conjunction with CAR T-cell expansion in vivo or in conjunction with 
conditioning-driven IL-15 pre-CAR T-cell infusion correlates with OR. CAR T-cell levels in 
blood measured by qPCR were correlated with clinical outcome. A composite index integrating 
PSI and CAR T-cell expansion in vivo was developed as detailed in the Online Methods and 
was associated with OR. The metrics were added to each other after each was first 
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standardized to have unit variance. This standardization was achieved by dividing the metrics 
by their respective standard deviation to bring them to a common magnitude/scale. Whole 
product PSI alone (A), peak CAR levels in blood alone (B), or product PSI in conjunction with 
peak CAR levels (C), are shown in association with OR. Pre-CAR T-cell infusion (day 0) IL-15 
serum levels alone (D) or in conjunction with product PSI (E) are shown in association with OR. 
Statistical values were computed using the Mann Whitney U test (P values were not adjusted for 
multiplicity).  
 
Table Legends 
Table 1. Patient demographics, clinical response, and AEs. The table depicts major 
demographic characteristics of the evaluable patients: age, gender, tumor histology (DLBCL, 
TFL, MCL, FL) and category (Aggressive, Indolent), and number of prior lines of therapy; the 
BRESP, and whether the subject had grade 3+ neurologic toxicities or grade 3+ CRS. CR, 
complete response; PR, partial response; BRESP, best response by Cheson criteria27; OR, 
objective response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; TFL, 
transformed follicular lymphoma; MCL, mantle cell lymphoma; PD, progressive disease; SD, 
stable disease. 
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Table 1. Patient demographics, clinical response, and AEs.  
ID Age Sex Lymphoma Lymphoma Category 
# Prior Lines 
of Therapy BRESP OR Subgroup Grade 3+ CRS Grade 3+ NT 
1 66.5 M DLBCL Aggressive 3 PR OR CRS - 
2 63.5 M FL Indolent 6 CR OR CRS NT 
3 65.3 M DLBCL Aggressive 4 PR OR CRS - 
4 47.1 M DLBCL Aggressive 2 PR OR - - 
5 28.8 M DLBCL Aggressive 7 PD - - - 
6 62.7 M DLBCL Aggressive 7 CR OR - NT 
7 54.7 M DLBCL Aggressive 3 PD - CRS - 
8 28.6 M DLBCL Aggressive 2 SD - - - 
9 29.5 M PMBCL Aggressive 3 SD - - - 
10 40.4 M PMBCL Aggressive 2 PD - - NT 
11 67.8 M DLBCL Aggressive 3 CR OR - NT 
12 50.4 M MCL Indolent 1 CR OR CRS NT 
13 53.2 M DLBCL Aggressive 4 CR OR CRS NT 
14 67.0 F FL Indolent 3 CR OR CRS NT 
15 51.9 M DLBCL Aggressive 3 CR OR CRS NT 
16 52.0 F DLBCL Aggressive 5 CR OR CRS NT 
17 39.0 M DLBCL Aggressive 4 PR OR CRS NT 
18 67.1 F DLBCL Aggressive 4 CR OR CRS NT 
19 64.4 M DLBCL Aggressive 4 CR OR CRS NT 
20 52.0 M DLBCL Aggressive 5 PD - CRS - 
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